Copies of SK Biopharmaceuticals Co.’s Xcopri proposed by MSN Laboratories Private Ltd. infringe a patent for the epilepsy drug, sales of which provide nearly all of SK’s revenue, according to a federal lawsuit.
SK Biopharm and its SK Life Science Inc. unit, both subsidiaries of South Korea-based SK Inc., allege MSN’s generic version of Xcopri infringes US Patent No. 11,654,133, according to a complaint filed Tuesday in the US District Court for the District of Delaware. MSN didn’t immediately respond to a request for comment.
- SK seeks an order blocking MSN’s copy until the June 2039 expiration of the patent, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.